FDA Schedules Type B Pre-NDA Meeting With Repros

THE WOODLANDS, Texas, Sept. 26, 2014  -- Repros Therapeutics Inc.^(R) (RPRX) today reported it has been granted a Type B Pre-NDA meeting with the FDA in the first half of November. In this meeting the Company will seek guidance on its planned New Drug Application (NDA) for Androxal^(R) for the treatment of secondary hypogonadism with preservation of testicular function. Repros believes that the NDA for Androxal^(R) will be filed around the end of 2014.

Dr. Andre Guay, Clinical Professor of Medicine (Endocrinology), Tufts University School of Medicine, Boston, MA, commented, "This news is encouraging as Androxal^(R), in my mind, is a compound that is not another form of exogenous testosterone replacement, but rather stimulates the body to make its own testosterone in men with secondary hypogonadism, which is the most common type of hypogonadism (approximately 80%), by our research and that of the European Male Aging Study."

About Repros Therapeutics Inc. ^(R)

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to planned clinical studies and the timing and nature of the results thereof, the impact of the studies on the Androxal^(R) label and the commercial potential of Androxal^(R) and the timing of the Company's expected filing of an NDA for Androxal^(R). Such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including the ability to have success in the clinical development of the Company's technologies, the reliability of interim results to predict final study outcomes, the ability to protect the Company's intellectual property rights and such other risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com.

Investor Relations:
Thomas Hoffmann
The Trout Group
(646) 378-2931
This email address is being protected from spambots. You need JavaScript enabled to view it.